Navigation Links
Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
Date:5/8/2013

tment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.  


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
2. Questcor Pharmaceuticals Expands Repurchase Program
3. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Adamis Pharmaceuticals CEO Provides Update for Shareholders
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
8. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
9. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
10. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
11. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... has been granted a patent by the United ... delivery system for delivering its "original" RNAi compounds ... treatment of diseases with an inflammatory component. Potential ...
(Date:9/17/2014)... Beckman Coulter , a global leader in ... its agreement with Personify for an additional ... will continue to streamline the Beckman Coulter talent acquisition ... time-to-fill, time-to-source and a deep reduction to cost-per-hire. , ... based on the success of our partnership over the ...
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
(Date:9/17/2014)... 2014 The Pistoia Alliance, a ... the barriers to innovation in life sciences R&D ... Carmen Nitsche as Executive Director Business Development North ... global reach. , Carmen joins the Pistoia Alliance ... Development. At Accelrys, she managed various life sciences ...
Breaking Biology Technology:RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... TSX symbol: SBS, CALGARY, Oct. 17 /PRNewswire-FirstCall/ ... (TSX:SBS), today announced that it has reached an,agreement ... funding for the,development of Botaneco as an independent ... a 27-month period, beginning in the fourth,quarter of ...
... KYPH ) announced today that its stockholders approved ... MDT ) at a special,meeting of stockholders held ... Kyphon entered into a,definitive merger agreement with Medtronic, pursuant ... shares of Kyphon common stock for,$71.00 per share in ...
... employed for a variety of uses including composite materials, ... proven useful for these purposes, no one really knows ... For example, how do nanotubes and chemical functional groups ... this question could lead to improvements in future nano ...
Cached Biology Technology:Botaneco obtains $2.4 million in funding from AVAC 2Botaneco obtains $2.4 million in funding from AVAC 3Kyphon Stockholders Approve Merger with Medtronic 2Researchers measure carbon nanotube interaction 2
(Date:9/17/2014)... After decades of decline, grasses have returned to ... eye, the marsh in those places seems healthy again, ... service of the marsh coastal protection remains ... ecosystem function hasn,t come back," said ecologist Mark Bertness, ... the study in the journal Biological Conservation . ...
(Date:9/17/2014)... significantly faster since the 1960s. The typical development phases ... have accelerated -- by as much as 70 percent. ... by scientists from Technische Universitt Mnchen based on long-term ... observed since 1870. Their findings were published recently in ... dieback" was a hot topic, with the very survival ...
(Date:9/17/2014)... crime unit designed to fight food fraud in ... being passed off as beef scientists from Germany ... describe their approach, which represents a vast improvement over ... Food Chemistry . , Hans-Ulrich Humpf and colleagues note ... But they also say that adding, for example, horse ...
Breaking Biology News(10 mins):Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... MADISON, WI, OCTOBER 12, 2009 Areas of ... and recreational (not grazing) purposes, i.e. "urban grasslands" are ... are over 150,000 km2of urban grasslands in the U.S. ... about nutrient runoff to streams, lakes, and estuaries and ...
... by a research group at the Sahlgrenska Academy at the ... of glandular cancer usually in the head and neck and ... to quicker and better diagnosis and more effective treatment. ... Proceedings of the National Academy of Sciences (PNAS). ...
... graphene more useful in electronics applications, Kansas State University ... graphene. Vikas Berry is a K-State assistant professor ... material only a single atom thick and discovered just ... thus controlling its electronics properties -- Berry and Kabeer ...
Cached Biology News:Nitrogen mysteries in urban grasslands 2Nitrogen mysteries in urban grasslands 3New cancer gene discovered 224-carat gold 'snowflakes' improve graphene's electrical properties 2
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Biology Products: